Rosacea Review - Newsletter of the National Rosacea SocietyRosacea Review - Newsletter of the National Rosacea Society

treatment

Have Rosacea? Time and Treatment Are on Your Side

Targeted rosacea therapies can lead to facial skin free of redness and blemishes, but only if these two key elements are also in place: the patient’s commitment to consistent adherence to the treatment plan and the patience to let it work. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to educate the public on this conspicuous, life-disruptive facial disorder affecting 16 million Americans, and urge those who may have it to see a dermatologist for diagnosis and therapy tailored to their individual case.

Tips for Success with New Therapy

While our culture offers many opportunities for instant gratification, unfortunately the management of rosacea is not one of them. 

“Patients should give any new treatment at least 12 weeks to do its job,” said Dr. Julie Harper, president and owner of the Dermatology and Skin Care Center of Birmingham and a member of the NRS medical advisory board.

Burning and Stinging Are Neglected But Important Symptoms in Managing Rosacea

Most clinical practice guidelines for rosacea identify the primary objective as clearing the visible signs of rosacea, while unseen symptoms such as burning and stinging are not always addressed even though they add to patients’ burden of disease and lower quality of life, according to a review of studies on burning and/or stinging in individuals with rosacea recently published in the European journal Acta Dermato-Venereologica.1

Eye Irritation Needs Special Attention

Soothing cleansing and other measures in addition to medical therapy may help relieve the symptoms of subtype 4 (ocular) rosacea, according to the standard management options for rosacea recently published by the National Rosacea Society (NRS).

"Gentle care in keeping eyelids clean is especially important in keeping eyes with ocular rosacea healthy," said Dr. Marian Macsai, professor of ophthalmology at the University of Chicago and a member of the consensus committee and review panel of 26 medical experts who developed the new standard options.1

Subscribe to treatment